top of page


The mission of ETHA is to give the thrombosis and hemostasis community a voice and to drive prioritisation of thrombosis and hemostasis in the EU patient safety and research programs. With a united focus on raising awareness of bleeding and clotting disorders, ETHA stands together to work with the public as well as decision makers' to provide input into EU health and patient safety strategies.

ETHA is dedicated to advocating for transformative scientific discoveries and clinical practices, the development and support of early career professionals and the education of physicians, scientists and allied health professionals to improve the lives of people in the EU.


ETHA is funded and administratively supported by the by the International Society on Thrombosis and Haemostasis (ISTH). It's work is guided by a Memorandum of Understanding (MOU). 


The Alliance seeks to:

  • Raise public and decision-makers’ awareness of thrombosis and hemostasis in terms of unmet health needs.

  • Nurture collaborations with stakeholders and national thrombosis and hemostasis organisations to become the ‘go-to’ partner to input into EU health and patient safety strategies.

  • Influence EU research and patient safety programmes to include thrombosis and hemostasis.

  • Encourage sharing and adoption of best practices across Member States.

Mettine Bos_Photo.jpg
Ingrid 2.png
Louise 2023.jpg


Chair, ETHA

Mettine Bos, Ph.D. is an assistant professor at the Leiden University Medical Center in the Netherlands. She completed her doctorate in biochemistry at Utrecht University. Her research interests are Biochemistry, Hematology, Molecular Biology, Cell Biology, Genetics, and Life Sciences.


Past Chair, ETHA

Ingrid Pabinger-Fasching, Ph.D., is a professor of Haemostaseology and vice-head of the Clinical Division of Haematology and Haemostaseology at the Medical University of Vienna, Austria. She has been principal investigator in many dozens of clinical trials and coordinating investigator in several international studies. She has published more than 480 papers (as of March 2022) in peer-reviewed journals, mainly in the fields of thrombosis, haemostasis, haematology and internal medicine.


Director of Marketing and External Relations, International Society on Thrombosis and Haemostasis

Louise St. Germain is an accomplished and innovative leader in marketing and global public affairs. With over 20 years of experience in the industry, she has a proven track record of developing and executing successful campaigns and public affairs strategies that have driven growth and success around the world.


Our success depends on creating an environment that welcomes, respects, and empowers our multicultural community in the EU. We foster a culture that celebrates unique identities and recognizes the contributions of all. We strive to harness the potential of our diverse community to deliver transformative research and clinical practices for the benefit of all people.

Every action of the ETHA is grounded in these guiding principles, and we commit to actions that advance the following:

  • Cultivate diverse leadership and visible representatives.

  • Create an inclusive environment that allows every member to fully participate and contribute.

  • Empower our members to champion diversity, equity and inclusion, and to hold each other accountable to these commitments.

Our vision is to provide a positive advocacy culture which supports all our members to reach their full potential. We aim to inspire our community to courageously question the status quo both within the ETHA, and in the community. Through these actions we aim to position the ETHA as a positive force in international efforts to promote equality to all people.

We are stronger together. The ETHA asks every member and collaborative partner to join us in forging this path towards a more equitable and inclusive future.

European Union Public Health Advocacy


As an alliance member of the ETHA, individuals and organizations can participate in the alliance's activities, including educational and training, research collaborations, and advocacy efforts to improve patient care and outcomes for those with thrombotic and haemostatic disorders. Members may also have access to resources and expertise within the alliance, as well as the opportunity to impact the public affairs activities within the European Parliament.

bottom of page